Skip to main content

Table 2 Correlations between clinicopathological features and Stathmin expression in all the included cases

From: The values of Transgelin, Stathmin, BCOR and Cyclin-D1 expression in differentiation between Uterine Leiomyosarcoma (ULMS) and Endometrial Stromal Sarcoma (ESS); diagnostic and prognostic implications

CharacteristicsAll (N = 44)Stathmin 
  Negative (N = 19)Focal weak +ve (N = 12)Diffuse strong +ve (N = 13)p-value
 No. (%)No. (%)No. (%)No. (%) 
Age (years)
 Mean ± SD56.84 ±7.9351.31 ±6.3062.33 ±6.5659.84 ±6.16<0.001*
 Median (Range)57 (39-72)50 (39-65)62.50 (52-72)60 (44-70) 
 ≤ 55 years18 (40.9%)15 (83.3%)2 (11.1%)1 (5.6%)<0.001‡
 > 55 years26 (59.1%)4 (15.4%)10 (38.5%)12 (46.2%) 
Histopathology
 LMS22 (50%)0 (0%)10 (45.5%)12 (54.5%)<0.001‡
 ESS22 (50%)19 (86.4%)2 (9.1%)1 (4.5%) 
Size
 <5 cm6 (13.6%)2 (33.3%)4 (66.7%)0 (0%)0.046‡
 >5 cm38 (86.4%)17 (44.7%)8 (21.1%)13 (34.2%) 
Grade
 Grade I9 (20.5%)4 (44.4%)5 (55.6%)0 (0%)0.015‡
 Grade II12 (27.3%)5 (41.7%)5 (41.7%)2 (16.7%) 
 Grade III23 (52.3%)10 (43.5%)2 (8.7%)11 (47.8%) 
Extrauterine extension
 Absent6 (13.6%)2 (33.3%)4 (66.7%)0 (0%)0.003‡
 Present9 (20.5%)4 (44.4%)5 (55.6%)0 (0%) 
 N/A29 (65.9%)13 (44.8%)3 (10.3%)13 (44.8%) 
LVSI
 Absent21 (47.7%)7 (33.3%)10 (47.6%)4 (19%)0.014‡
 Present23 (52.3%)12 (52.2%)2 (8.7%)9 (39.1%) 
Adnexal invasion
 Absent11 (25%)4 (36.4%)7 (63.6%)0 (0%)0.003‡
 Present33 (75%)15 (45.5%)5 (15.2%)13 (39.4%) 
Lymph node
 Negative16 (36.4%)6 (37.5%)10 (62.5%)0 (0%)<0.001‡
 Positive28 (63.6%)13 (46.4%)2 (7.1%)13 (46.4%) 
FIGO Stage
 Stage I6 (13.6%)2 (33.3%)4 (66.7%)0 (0%)0.001‡
 Stage II10 (22.7%)4 (40%)6 (60%)0 (0%) 
 Stage III13 (29.5%)5 (38.5%)0 (0%)8 (61.5%) 
 Stage IV15 (34.1%)8 (53.3%)2 (13.3%)5 (33.3%) 
Transgelin
 Negative25 (56.8%)19 (76%)5 (20%)1 (4%)<0.001‡
 Focal weak +ve6 (13.6%)0 (0%)6 (100%)0 (0%0 
 Diffuse strong +ve13 (29.5%)0 (0%)1 (7.7%)12 (92.3%) 
BCOR
 Negative23 (52.3%)4 (17.4%)10 (43.5%)9 (39.1%)0.007‡
 Focal weak +ve7 (15.9%)5 (71.4%)0 (0%)2 (28.6%) 
 Diffuse strong +ve14 (31.8%)10 (71.4%)2 (14.3%)2 (14.3%) 
Cyclin-D1
 Negative24 (54.5%)2 (8.3%)10 (41.7%)12 (50%)<0.001‡
 Focal weak +ve5 (11.4%)5 (100%)0 (0%)0 (0%) 
 Diffuse strong +ve15 (34.1%)12 (80%)2 (13.3%)1 (6.7%) 
  1. * Kruskal Wallis H test; ‡ Chi-square test; p< 0.05 is significant